Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-PROT-23

ABSTRACT: Proteomics characterization of human colon and rectal cancer

PROVIDER: E-PROT-23 | ExpressionAtlas | 2024-02-23

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-PROT-23-analysis-methods.tsv	Tabular
	E-PROT-23-configuration.xml	Xml
	E-PROT-23-factors.xml	Xml
	E-PROT-23.condensed-sdrf.tsv	Tabular
	E-PROT-23.idf.txt	Idf

Items per page:

1 - 5 of 12

Similar Datasets

Homo sapiens

Project description:Comprehensive Molecular Characterization of Human Colon and Rectal Cancer

| PRJNA174201 | ENA

Intra-tumoral heterogeneity in metastatic potential and survival signaling between iso-clonal HCT116 and HCT116b human colon carcinoma cell lines

Project description:Characterization of the intra-tumoral heterogeneity between two iso-clonal human colon cancer sublines HCT116 and HCT116b on their ability to undergo metastatic colonization and survive under growth factor deprivation stress (GFDS). Microarray analysis revealed an upregulation of survival and metastatic genes in the highly metastatic HCT116 primary colon tumor cells compared to the poorly metastatic HCT116b primary colon tumor cells. Total RNA obtained from isolated primary colon tumors of HCT116 and HCT116b xenograft transplanted animals obtained using the orthotopic implantation of HCT116 and HCT116b human colon cancer xenografts in the cecum of male athymic BALB/c nude mice were compared at their gene expression level.

2013-02-20 | E-GEOD-44381 | biostudies-arrayexpress

Intra-tumoral heterogeneity in metastatic potential and survival signaling between iso-clonal HCT116 and HCT116b human colon carcinoma cell lines

2013-02-20 | GSE44381 | GEO

Differences in RNA expression between primary and metastatic colon tumor

Project description:Here, we report the genomic-scale characterization of metastatic colon cancer transcriptome. Fresh-frozen samples was used to asses differences between normal colon, primary colon tumor an liver metastasis.

2018-09-22 | GSE89393 | GEO

Project description:Proteogenomic characterization of human colon cancer reveals new therapeutic opportunities

| PRJNA514017 | ENA

Mass spectrometry data of colon cancer cell SW480 treated with Caffeic acid phenyl ethyl

Project description:Caffeic acid acetophenate exhibits anti-tumor activity. We employed proteomics to investigate the targets of caffeic acid acetophenate in human colon cancer cells. The experimental group consisted of SW480 human colon cancer cells treated with 10μM caffeic acid phenethyl for 24 hours, while the control group was treated with an equivalent volume of DMSO. Non-standard quantitative mass spectrometry was utilized to analyze differentially expressed proteins between the two groups and identify the specific target of caffeic acid acetophenate on colon cancer cells.

2023-11-01 | PXD046600 |

Transcriptome of locally advanced colorectal tumours

Project description:Here, we report the genomic-scale characterization of locally advanced colon cancer transcriptome. Paraffin embedded samples was used to asses differences between normal colon, primary colon tumor an lymph node metastasis.

2019-05-02 | GSE100243 | GEO

Human MSI colon cancer

Project description:Human MSI colon cancer

| PRJNA666078 | ENA

Overexpression of Mitochondrial Aconitase in HT29 Colon Cancer Cells Attenuates beta-Catenin Signaling Pathway via Metabolic Changes of NADPH and ROS

Project description:Our previous proteomics analysis suggested down-regulation of mitochondrial aconitase (ACO2) plays an important role in colorectal cancer. To evaluate the effect of mitochondrial aconitase overexpression on the metabolic and signaling pathway changes in colon cancer cell line HT29, we generated two ACO2 overexpressing cell lines #C and #UD and the mock-transfected vector control #VE. HT29 colon cancer cells overexpressing ACO2 exhibited lower rate of cell proliferation in vitro and reduced tumor growth potential in nude mice. In order to understand the signaling pathway changes, cDNA microarray analysis using GeneChips from Affymetrix were carried out.

2010-01-14 | E-MEXP-1996 | biostudies-arrayexpress

Obesity facilitated colon cancer progression is mediated by increased diacylglycerol o-acyltransferases 1 and 2 (DGAT1/2) levels

Project description:Background & Aims: The obesity epidemic is associated with increased colon cancer progression. As lipid droplets (LDs) fuel tumor growth, we aim to determine the significance of diacyltransferases, DGAT1/2, responsible for LDs biogenesis, in obesity-mediated colonic tumorigenesis. Methods: Human colon cancer samples, colon cancer cells, colonospheres, and ApcMin/+ colon cancer mouse model on a high-fat diet were employed. For DGAT1/2 inhibition, enzymatic inhibitors and siRNA were used. Expression, pathways, cell cycle, and growth were assessed. Bioinformatic analysis of CUT&RUN and RNAseq data was performed. Results: DGAT1/2 levels in human colon cancer tissue are significantly elevated with disease severity and obesity (vs normal). Their levels are increased in human colon cancer cells (vs non-transformed) and further enhanced by fatty acids prevalent in obesity; augmented DGAT2 expression is MYC-dependent. Inhibition of DGAT1/2 improves FOXO3 activity by attenuating PI3K, resulting in reduced MYC-dependent DGAT2 expression and LDs accumulation, suggesting feedback. This inhibition attenuated growth in colon cancer cells and colonospheres via FOXO3/p27kip1 cell cycle arrest and reduced colonic tumors in ApcMin/+ mice on a high-fat diet. Transcriptomic analysis revealed that DGAT1/2 inhibition targeted metabolic and tumorigenic pathways in human colon cancer and colon cancer crypts, stratifying human colon cancer samples from normal. Further analysis revealed that this inhibition is predictive of advanced disease-free state and survival in colon cancer patients. Conclusion: This is a novel mechanism of DGAT1/2-dependent metabolic and tumorigenic remodeling in obesity-facilitated colon cancer, which provides a platform for the future development of effective treatments for colon cancer patients.

2024-10-14 | GSE278787 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data